文献速递神经介入DSA

海绵窦区硬脑膜动静脉瘘的靶向栓塞血管内治疗:单中心研究

Endovascular Treatment With Targeted Embolization of Cavernous Sinus Dural Arteriovenous Fistulas: A Single-Center Study.
PubMed 文献 · Korean J Radiol · 2024-11-08

该回顾性单中心研究纳入1991年10月至2023年3月接受血管内治疗的198例海绵窦区硬脑膜动静脉瘘患者,按临床和分流特征选择靶向、非靶向或姑息栓塞。靶向栓塞组(94例)术后即刻DSA完全或近完全闭塞率93.6%,并发症率2.1%,症状改善率96.8%,再治疗率5.3%,随访无严重并发症。作者认为靶向栓塞成功时颅神经麻痹、再治疗率低且临床结局良好。

要点

  • 靶向栓塞用于局灶性(限制型或迟发限制型)瘘,弥漫性(增殖型)瘘多行非靶向或姑息栓塞。
  • 靶向栓塞组术后即刻DSA完全或近完全闭塞率93.6%(88/94)。
  • 靶向栓塞组并发症率2.1%(2/94),症状改善率96.8%(91/94),再治疗率5.3%(5/94)。

核心结论

  • 靶向栓塞成功时,海绵窦区硬脑膜动静脉瘘的颅神经麻痹率、再治疗率低且临床结局良好。

研究设计与样本

  • 回顾性单中心研究,纳入1991年10月至2023年3月一家三级医院接受血管内治疗的198例海绵窦区硬脑膜动静脉瘘患者,治疗策略依据临床症状和分流特征确定,以术后DSA评估闭塞情况。

诊断标准与关键数值

  • 靶向栓塞定义为选择性闭塞分流囊而保留正常海绵窦腔,失败后行非靶向栓塞;姑息栓塞仅减少分流流量。靶向栓塞组术后即刻DSA完全或近完全闭塞率93.6%(88/94),并发症率2.1%(2/94),症状改善率96.8%(91/94),再治疗率5.3%(5/94)。

临床应用与阅片要点

  • 作者认为靶向栓塞成功时颅神经麻痹率、再治疗率低且临床结局良好;局灶性(限制型或迟发限制型)瘘通常采用靶向栓塞,弥漫性(增殖型)瘘多行非靶向或姑息栓塞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the feasibility, efficacy, and safety of targeted embolization for cavernous sinus dural arteriovenous fistulas (CSDAVF).

MATERIALS AND METHODS: This retrospective study investigated patients with CSDAVF who underwent endovascular treatment at a tertiary hospital between October 1991 and March 2023. Treatment strategies were determined based on clinical symptoms and shunt characteristics. Targeted or non-targeted curative embolization was performed to achieve complete shunt occlusion. Initially, targeted embolization, selective occlusion of the shunted pouch while preserving the normal cavernous sinus lumen, was conducted, should that fail, non-targeted embolization was performed. In contrast, palliative embolization solely reduced shunt flow. Clinical signs, imaging characteristics, and outcomes were evaluated according to the agreed treatment strategy.

RESULTS: In total, 198 patients with CSDAVF (mean age 59.0 ± 12.1 years, 23.2% male) participated in this study. Of which, 94 patients (47.5%) were treated with targeted embolization, 75 (37.9%) with non-targeted embolization, and 29 (14.6%) with palliative treatment. For patients undergoing curative embolization, 55.7% (94/169) successfully achieved targeted embolization; this procedure was usually used to treat focal fistulas (restrictive or late-restrictive types), whereas diffuse fistulas (proliferative type) often underwent non-targeted or palliative embolization. For patients that underwent targeted embolization, the rate of complete or near-complete occlusion on immediate post-treatment digital subtraction angiography was 93.6% (88/94), with a complication rate of 2.1% (2/94), symptom improvement rate of 96.8% (91/94), and retreatment rate of 5.3% (5/94). No serious complications were reported during follow-up.

CONCLUSION: When successful, targeted embolization of CSDAVF causes low rates of cranial nerve palsy, retreatment, and good clinical outcomes.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Park S, Lee K, Moon E, et al. Endovascular Treatment With Targeted Embolization of Cavernous Sinus Dural Arteriovenous Fistulas: A Single-Center Study. Korean J Radiol. 2024. PMID: 39543865. doi:10.3348/kjr.2024.0351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。